Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a high
metastatic potential. Monoclonal antibodies (mAbs) that target HER2, such as trastuzumab …

Systemic drug delivery is the current clinically preferred route for cancer therapy. However,
challenges associated with tumor localization and off-tumor toxic effects limit the clinical …

In this work, we conceived and developed antibody-drug conjugates (ADCs) that could
efficiently release the drug after enzymatic cleavage of the linker moiety by tumoral …

Over the past two decades, metronomic chemotherapy has gained considerable attention
and has demonstrated remarkable success in the treatment of cancer. Through chronic …

Simple Summary The development of drug resistance in HER2 targeted therapies poses a
major challenge in breast cancer treatment. To address this challenge, researchers have …

Breast cancer (BC) is the most prevalent malignancy in women and researchers have
strived to develop optimal strategies for its diagnosis and management. Neoadjuvant …

Breast cancer poses one of the largest threats to women's health. Treatment continues to
improve for all the subtypes of breast cancer, but some subtypes, such as triple negative …

Breast cancer is a heterogeneous disease and is the most prevalent cancer in women.
According to the US breast cancer statistics, about 1 in every 8 women develop an invasive …

Background The PHILA study suggests that pyrotinib, trastuzumab, and docetaxel
significantly improved progression-free survival (PFS) compared with placebo, trastuzumab …

Introduction Immunotherapies have found limited success in breast cancerdue to significant
challenges within the tumor that block T-cell activity and function. Areas covered The current …